Rokit Healthcare has received clinical approval to begin the world's first human kidney regeneration surgery in July 2026. The South Korean company's approach uses cells harvested from a patient's own omentum — a fatty tissue layer in the abdomen — combined with AI-driven 3D bioprinting and robotic surgery. The omentum patch was classified as low-risk by regulators, and safety was confirmed through large animal studies. This trial will initially assess safety and early regenerative potential. For the roughly 850 million people worldwide living with kidney disease, a regenerative solution could represent a major alternative to dialysis or transplant. Full treatment approval is targeted for late 2026.
